Alpha 2.0
Login Register
» Authors » Akihito Tsuji

Akihito Tsuji

Explore the profile of Akihito Tsuji including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 142
Citations 3960
Followers 0
Related Specialties
Oncology
Gastroenterology
General Medicine
Top 10 Co-Authors
Hisateru Yasui
Tomohiro Nishina
Masahito Kotaka
Eiji Oki
Hironaga Satake
Takayuki Yoshino
Kentaro Yamazaki
Tadamichi Denda
Takeshi Kato
Kei Muro
Published In
Int J Clin Oncol
Cancer Chemother Pharmacol
Gan To Kagaku Ryoho
Gastric Cancer
BMC Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
A phase two trial evaluating FOLFIRI plus aflibercept after failure of FOLFOXIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer
Ando K, Satake H, Shimokawa M, Yasui H, Negoro Y, Kinjo T, et al.
Int J Clin Oncol . 2025 Feb; 30(3):514-523. PMID: 39891883
Background: FOLFOXIRI plus bevacizumab (BEV) is an option for first-line treatment of metastatic colorectal cancer (mCRC). However, there is no consensus on the optimal treatment strategy when disease progresses. The...
2.
Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial
Shiozawa M, Sunakawa Y, Watanabe T, Ota H, Yasui H, Yabuno T, et al.
Nat Commun . 2024 Nov; 15(1):10217. PMID: 39587053
The clinical significance of FOLFOXIRI (5-FU, leucovorin, oxaliplatin, and irinotecan) plus anti-EGFR monoclonal antibody using cetuximab for metastatic colorectal cancer (mCRC) remains controversial. We report results from a randomized phase...
3.
[A Case of Intrahepatic Cholangiocarcinoma and Early Postoperative Recurrences Using Comprehensive Genome Profiling to Implement Effective Treatment]
Yotsumoto T, Ando Y, Sakamoto A, Feng D, Nagao M, Matsukawa H, et al.
Gan To Kagaku Ryoho . 2024 Jul; 51(6):659-662. PMID: 39009526
Subsequent to a medical examination, a 61-year-old male was referred to our hospital with jaundice. He was diagnosed with intrahepatic cholangiocarcinoma involving the hepatic hilum and was referred to our...
4.
QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC
Bando H, Kotani D, Satake H, Hamaguchi T, Shiozawa M, Kotaka M, et al.
Med . 2024 Jun; 5(9):1164-1177.e3. PMID: 38901425
Background: The QUATTRO-II trial examined the efficacy and safety of capecitabine+oxaliplatin+irinotecan (CAPOXIRI)+bevacizumab (BEV) vs. 5-fluorouracil+folinic acid+oxaliplatin+irinotecan (FOLFOXIRI)+BEV in metastatic colorectal cancer (mCRC). Methods: In this phase II study (ClinicalTrials.gov: NCT04097444;...
5.
First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study
Kato K, Kojima T, Hara H, Tsuji A, Yasui H, Muro K, et al.
Esophagus . 2024 Apr; 21(3):306-318. PMID: 38607538
Background: First-line pembrolizumab plus chemotherapy (pembrolizumab-chemotherapy) demonstrated improved efficacy and a manageable safety profile versus placebo plus chemotherapy (placebo-chemotherapy) in the subgroup analysis of Japanese patients with advanced/metastatic esophageal cancer...
6.
Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study
Yuki S, Yamazaki K, Sunakawa Y, Taniguchi H, Bando H, Shiozawa M, et al.
Clin Colorectal Cancer . 2024 Feb; 23(2):147-159.e7. PMID: 38331650
Background: The significance of angiogenic factors as predictors of second-line (2L) chemotherapy efficacy when combined with angiogenesis inhibitors for metastatic colorectal cancer (mCRC) remains unestablished. Patients And Methods: In this...
7.
Third Report of the Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on diabetes and cancer: summary of the results of a questionnaire survey of oncologists and diabetologists-secondary publication
Goto A, Ohashi K, Noda M, Noto H, Ueki K, Inoue M, et al.
Diabetol Int . 2024 Jan; 15(1):5-18. PMID: 38264218
The Japan Diabetes Society (JDS) and the Japan Cancer Association (JCA) launched a joint committee and published their "First Joint Committee Report on Diabetes and Cancer" in 2013, compiling recommendations...
8.
Third Report of the Japan Diabetes Society/Japanese Cancer Association Joint Committee on Diabetes and Cancer: Summary of the results of a questionnaire survey of oncologists and diabetologists-Secondary publication
Goto A, Ohashi K, Noda M, Noto H, Ueki K, Inoue M, et al.
Cancer Sci . 2024 Jan; 115(2):672-681. PMID: 38184804
The Japan Diabetes Society and the Japan Cancer Association launched a joint committee and published their "First Joint Committee Report on Diabetes and Cancer" in 2013, compiling recommendations for physicians...
9.
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)
Ando K, Nakamura Y, Kitao H, Shimokawa M, Kotani D, Bando H, et al.
Br J Cancer . 2023 Aug; 129(6):1032-1039. PMID: 37532830
Background: Although nivolumab has a high efficacy, reliable biomarkers are needed to predict the efficacy. We evaluated the nivolumab efficacy according to the TP53 mutation in advanced gastric cancer patients...
10.
The BEETS (JACCRO CC-18) trial: an observational and translational study of -mutated metastatic colorectal cancer
Inagaki C, Matoba R, Yuki S, Shiozawa M, Tsuji A, Inoue E, et al.
Future Oncol . 2023 Jul; 19(17):1165-1174. PMID: 37458152
For V600E-mutated metastatic colorectal cancer (mCRC), the BEACON phase 3 trial showed survival benefit of triplet therapy with cetuximab (anti-EGFR antibody), encorafenib (BRAF inhibitor) and binimetinib (MEK inhibitor) as well...